WO1999001151A1 - Use of growth hormone in compositions for treating insulin resistance in the heart and for enhancing protein kinase b (pkb) activity - Google Patents
Use of growth hormone in compositions for treating insulin resistance in the heart and for enhancing protein kinase b (pkb) activity Download PDFInfo
- Publication number
- WO1999001151A1 WO1999001151A1 PCT/SE1998/001261 SE9801261W WO9901151A1 WO 1999001151 A1 WO1999001151 A1 WO 1999001151A1 SE 9801261 W SE9801261 W SE 9801261W WO 9901151 A1 WO9901151 A1 WO 9901151A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- heart
- insulin resistance
- growth hormone
- use according
- insulin
- Prior art date
Links
- 208000001072 type 2 diabetes mellitus Diseases 0.000 title claims abstract description 39
- 206010022489 Insulin Resistance Diseases 0.000 title claims abstract description 38
- 108091008611 Protein Kinase B Proteins 0.000 title claims description 23
- 102000005765 Proto-Oncogene Proteins c-akt Human genes 0.000 title claims description 22
- 230000000694 effects Effects 0.000 title claims description 12
- 230000002708 enhancing effect Effects 0.000 title claims description 3
- 239000000122 growth hormone Substances 0.000 title description 13
- 102000018997 Growth Hormone Human genes 0.000 title description 12
- 108010051696 Growth Hormone Proteins 0.000 title description 12
- 239000000203 mixture Substances 0.000 title description 5
- 102000002265 Human Growth Hormone Human genes 0.000 claims abstract description 36
- 108010000521 Human Growth Hormone Proteins 0.000 claims abstract description 36
- 239000000854 Human Growth Hormone Substances 0.000 claims abstract description 36
- 239000008103 glucose Substances 0.000 claims description 22
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 20
- 230000000747 cardiac effect Effects 0.000 claims description 13
- 238000011282 treatment Methods 0.000 claims description 12
- 206010012601 diabetes mellitus Diseases 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- 230000003647 oxidation Effects 0.000 claims description 9
- 238000007254 oxidation reaction Methods 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 230000001976 improved effect Effects 0.000 claims description 7
- 238000012360 testing method Methods 0.000 claims description 6
- 206010007558 Cardiac failure chronic Diseases 0.000 claims description 5
- 230000008828 contractile function Effects 0.000 claims description 5
- 206010007556 Cardiac failure acute Diseases 0.000 claims description 4
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 4
- 239000000194 fatty acid Substances 0.000 claims description 4
- 229930195729 fatty acid Natural products 0.000 claims description 4
- 150000004665 fatty acids Chemical class 0.000 claims description 4
- 230000004153 glucose metabolism Effects 0.000 claims description 4
- 238000009578 growth hormone therapy Methods 0.000 claims description 4
- 238000001356 surgical procedure Methods 0.000 claims description 4
- 230000001684 chronic effect Effects 0.000 claims description 3
- 210000002064 heart cell Anatomy 0.000 claims description 3
- 230000004217 heart function Effects 0.000 claims description 3
- 230000000472 traumatic effect Effects 0.000 claims description 3
- 230000017531 blood circulation Effects 0.000 claims description 2
- 230000001010 compromised effect Effects 0.000 claims description 2
- 230000000717 retained effect Effects 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 abstract description 10
- 230000003915 cell function Effects 0.000 abstract description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 46
- 210000004027 cell Anatomy 0.000 description 33
- 210000004413 cardiac myocyte Anatomy 0.000 description 29
- 102000004877 Insulin Human genes 0.000 description 24
- 108090001061 Insulin Proteins 0.000 description 24
- 229940125396 insulin Drugs 0.000 description 24
- 230000006907 apoptotic process Effects 0.000 description 9
- 230000030833 cell death Effects 0.000 description 9
- 230000006377 glucose transport Effects 0.000 description 9
- 230000004913 activation Effects 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 239000012679 serum free medium Substances 0.000 description 8
- QDLHCMPXEPAAMD-QAIWCSMKSA-N wortmannin Chemical compound C1([C@]2(C)C3=C(C4=O)OC=C3C(=O)O[C@@H]2COC)=C4[C@@H]2CCC(=O)[C@@]2(C)C[C@H]1OC(C)=O QDLHCMPXEPAAMD-QAIWCSMKSA-N 0.000 description 8
- QDLHCMPXEPAAMD-UHFFFAOYSA-N wortmannin Natural products COCC1OC(=O)C2=COC(C3=O)=C2C1(C)C1=C3C2CCC(=O)C2(C)CC1OC(C)=O QDLHCMPXEPAAMD-UHFFFAOYSA-N 0.000 description 8
- ZIIQCSMRQKCOCT-UHFFFAOYSA-N 2-acetamido-3-methyl-3-nitrososulfanylbutanoic acid Chemical compound CC(=O)NC(C(O)=O)C(C)(C)SN=O ZIIQCSMRQKCOCT-UHFFFAOYSA-N 0.000 description 7
- 206010019280 Heart failures Diseases 0.000 description 7
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 7
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 230000035882 stress Effects 0.000 description 7
- 102100020948 Growth hormone receptor Human genes 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 229930192392 Mitomycin Natural products 0.000 description 6
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 6
- 108091007960 PI3Ks Proteins 0.000 description 6
- 230000009471 action Effects 0.000 description 6
- 229960004857 mitomycin Drugs 0.000 description 6
- 230000011664 signaling Effects 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 230000001154 acute effect Effects 0.000 description 5
- 230000004224 protection Effects 0.000 description 5
- 102000003746 Insulin Receptor Human genes 0.000 description 4
- 108010001127 Insulin Receptor Proteins 0.000 description 4
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 4
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 230000002608 insulinlike Effects 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 230000001590 oxidative effect Effects 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 101710099093 Growth hormone receptor Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 108010068542 Somatotropin Receptors Proteins 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000004190 glucose uptake Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 206010007559 Cardiac failure congestive Diseases 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 102000001267 GSK3 Human genes 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 235000021314 Palmitic acid Nutrition 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000013553 cell monolayer Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 235000020805 dietary restrictions Nutrition 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 229940063135 genotropin Drugs 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000001117 sulphuric acid Substances 0.000 description 2
- 235000011149 sulphuric acid Nutrition 0.000 description 2
- 230000009469 supplementation Effects 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- VRYALKFFQXWPIH-PBXRRBTRSA-N (3r,4s,5r)-3,4,5,6-tetrahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)CC=O VRYALKFFQXWPIH-PBXRRBTRSA-N 0.000 description 1
- 102000003737 3-Phosphoinositide-Dependent Protein Kinases Human genes 0.000 description 1
- 108010082078 3-Phosphoinositide-Dependent Protein Kinases Proteins 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000004420 Creatine Kinase Human genes 0.000 description 1
- 108010042126 Creatine kinase Proteins 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- YXWOAJXNVLXPMU-ZXXMMSQZSA-N Fructose 2,6-diphosphate Chemical compound OP(=O)(O)O[C@]1(CO)O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O YXWOAJXNVLXPMU-ZXXMMSQZSA-N 0.000 description 1
- 108060006662 GSK3 Proteins 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 108010014905 Glycogen Synthase Kinase 3 Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 101150088952 IGF1 gene Proteins 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101000985214 Mus musculus 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102000012434 Phosphofructokinase-2 Human genes 0.000 description 1
- 108010022678 Phosphofructokinase-2 Proteins 0.000 description 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 102100030264 Pleckstrin Human genes 0.000 description 1
- 102000013535 Proto-Oncogene Proteins c-bcl-2 Human genes 0.000 description 1
- 108010090931 Proto-Oncogene Proteins c-bcl-2 Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102000001712 STAT5 Transcription Factor Human genes 0.000 description 1
- 108010029477 STAT5 Transcription Factor Proteins 0.000 description 1
- 101000930762 Sulfolobus acidocaldarius (strain ATCC 33909 / DSM 639 / JCM 8929 / NBRC 15157 / NCIMB 11770) Signal recognition particle receptor FtsY Proteins 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 1
- GBOGMAARMMDZGR-UHFFFAOYSA-N UNPD149280 Natural products N1C(=O)C23OC(=O)C=CC(O)CCCC(C)CC=CC3C(O)C(=C)C(C)C2C1CC1=CC=CC=C1 GBOGMAARMMDZGR-UHFFFAOYSA-N 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- RQQIRMLGKSPXSE-WIPMOJCBSA-N [1-acetyloxy-2-[[(2s,3r,5s,6s)-2,6-dihydroxy-3,4,5-triphosphonooxycyclohexyl]oxy-hydroxyphosphoryl]oxyethyl] acetate Chemical compound CC(=O)OC(OC(C)=O)COP(O)(=O)OC1[C@H](O)[C@H](OP(O)(O)=O)C(OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H]1O RQQIRMLGKSPXSE-WIPMOJCBSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000001800 adrenalinergic effect Effects 0.000 description 1
- 230000003281 allosteric effect Effects 0.000 description 1
- PMMURAAUARKVCB-UHFFFAOYSA-N alpha-D-ara-dHexp Natural products OCC1OC(O)CC(O)C1O PMMURAAUARKVCB-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000008081 blood perfusion Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 229940030602 cardiac therapy drug Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000037326 chronic stress Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000009091 contractile dysfunction Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 229940095074 cyclic amp Drugs 0.000 description 1
- GBOGMAARMMDZGR-JREHFAHYSA-N cytochalasin B Natural products C[C@H]1CCC[C@@H](O)C=CC(=O)O[C@@]23[C@H](C=CC1)[C@H](O)C(=C)[C@@H](C)[C@@H]2[C@H](Cc4ccccc4)NC3=O GBOGMAARMMDZGR-JREHFAHYSA-N 0.000 description 1
- GBOGMAARMMDZGR-TYHYBEHESA-N cytochalasin B Chemical compound C([C@H]1[C@@H]2[C@@H](C([C@@H](O)[C@@H]3/C=C/C[C@H](C)CCC[C@@H](O)/C=C/C(=O)O[C@@]23C(=O)N1)=C)C)C1=CC=CC=C1 GBOGMAARMMDZGR-TYHYBEHESA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical group O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 239000012909 foetal bovine serum Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 208000022368 idiopathic cardiomyopathy Diseases 0.000 description 1
- 239000012133 immunoprecipitate Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004155 insulin signaling pathway Effects 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000005567 liquid scintillation counting Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- NFVJNJQRWPQVOA-UHFFFAOYSA-N n-[2-chloro-5-(trifluoromethyl)phenyl]-2-[3-(4-ethyl-5-ethylsulfanyl-1,2,4-triazol-3-yl)piperidin-1-yl]acetamide Chemical compound CCN1C(SCC)=NN=C1C1CN(CC(=O)NC=2C(=CC=C(C=2)C(F)(F)F)Cl)CCC1 NFVJNJQRWPQVOA-UHFFFAOYSA-N 0.000 description 1
- 239000002840 nitric oxide donor Substances 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 238000007410 oral glucose tolerance test Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 108010026735 platelet protein P47 Proteins 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000011946 reduction process Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000005167 vascular cell Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
Definitions
- the present invention relates to a therapy involving administration of human growth hormone for improving cellular function in the heart challenged by insulin resistance and thereby treating or protecting the heart from complications derivable from this condition.
- insulin resistance in the heart can precipitate heart failure by itself or predispose for serious complication in the stressed heart, which may follow traumatic events such as acute coronary events, congestive heart failure and coronary surgery.
- the insulin resistance is treated by applying supra-physiological levels of circulating insulin, by enhancers of insulin action or by dietary restrictions.
- Such therapies have severe draw-backs or limitations in efficacy with regards to insulin resistance in general.
- An increased concentration of circulating insulin can cause hyper-proliferation in vascular cells and thereby disturb tissue blood supply.
- insulin enhancers tend to increase body fat mass which in turn is a risk factor in heart disease and dietary restriction is primarily targeted for uncomplicated type 2 diabetes.
- there is as yet no therapy which has been proven to be efficient in the treatment of complications resulting from insulin resistance in the heart.
- PI3K phosphoinositide 3- kinase
- PKB inhibits BAD (a member of the BCL2 protein family) by phosphorylation, thereby preventing the apoptotic promoting effect of BAD (see del-Peso-L et al, Science, 1997, 278 (5338):687-9; Datta et al. Cell, 1997;91(2):231-41).
- PKB appears to be a key intermediary in the regulation of glucose utilisation and control of protein synthesis by insulin (Cross, D., et al. (1995). Nature 378: 785- 789; Cohen, Pet al. (1997). FEBS Letters 410: 3-10; Peak, M., J. et al. (1998).
- PKB has been shown to phosphorylate and activate phosphofructo kinase-2 ( Deprez, D et al. (1997) Journal of Biological Chemistry 272: 17269-17275) whose product, fructose 2,6-bisphosphate, acts as an allosteric activator of glycolysis.
- a third likely substrate for PKB is the type 3B cyclic AMP phosphodiesterase ( Wijkander, J. et al. (1998). Endocrinology 139: 219-227), which in insulin-responsive tissues is activated by phosphorylation, leading to the inactivation of adrenergic-stimulated processes.
- the present invention is based on the finding that human growth hormone can exert insulin-like effects in cardiac cells and thereby is capable of replacing this hormone during insulin resistance.
- the present invention relates to the utility of an effective amount of human growth hormone in the preparation of an agent for the administration to a patient, having or being at risk of acquiring insulin resistance in the heart. More particularly, the present invention relates to the use of an effective dose of human growth hormone in the preparation of an agent for retaining an adequate metabolism and resistance to stress in the heart challenged by insulin resistance and to prevent the heart from complications derived from insulin resistance.
- the insulin resistance may be induced by chronic stress or traumatic events including surgery, but it may also derive from conditions related to diabetes.
- the inventive therapy is specifically targeted to normalize a disturbed cardiac metabolism, including glucose transportation, glucose oxidation and fatty acid oxidation, to achieve a sufficient coronary blood flow or to induce protection against stress-induced cell death in order to maintain an adequate cardiac contractile function which may eventually precipitate as a result of a diminished insulin receptor dependent signaling in the heart.
- inventive growth hormone therapy enhances the activity of PKB (Protein Kinase B) which is a key intermediary agent in the regulation of glucose utilization and control of protein synthesis by insulin. Consequently, growth hormone preparations can be used for improving a compromised heart function common in acute failure caused by e.g. myocardial infarction, hypertension, genetic disorders, as well as complications resulting from insulin resistance and thereby treating or protecting the heart.
- the present invention constitutes a suitable treatment especially for patients suffering from diabetes involving insulin resistance and have, or are at risk of acquiring, cardiac complications. Furthermore, patients suffering from chronic and acute heart failure will benefit from the therapy if they are exposed to conditions, such as stress or trauma from which insulin resistance is developed. The skilled physician will be able to judge which disorders may develop into insulin resistance and thereby further challenge such cardiac patients. Furthermore, according to the present invention, it is also possible to determine whether an individual, who has or is at risk of acquiring cardiac complications, is eligible for a treatment with human growth hormone by subjecting the patient to an insulin resistance test, for example an oral glucose tolerance tests, glucose/clamp analysis or analysis of the fasting blood glucose level.
- an insulin resistance test for example an oral glucose tolerance tests, glucose/clamp analysis or analysis of the fasting blood glucose level.
- a test allowing for a specific determination of the insulin resistance in the heart is also applicable when suitable to apply, as for example in connection with bypass surgery.
- Such tests will provide a simple and efficient prognostic diagnostic tool for determining if the patient will benefit from a human growth hormone therapy for treating or preventing the heart from further complications due to insulin resistance.
- the inventive utility of human growth hormone will consequently be especially powerful in pathological states where insulin is prevented from exerting its full action (insulin resistance) and where cardiac complications clearly are developing.
- the cardiac complications associated with insulin resistance can be clinically defined as chronic ischemia, contractile dysfunction or congestion.
- the cardiac insufficiency can be identified by cardiac enzyme leakage into the blood such as cardiac isoforms of creatine kinase and troponin, an inadequate blood perfusion of the heart, a deranged metabolism exemplified by a low glucose up-take and high lactate production, a malfunctioning calcium regulation or an increase in cell death.
- cardiac enzyme leakage into the blood such as cardiac isoforms of creatine kinase and troponin, an inadequate blood perfusion of the heart, a deranged metabolism exemplified by a low glucose up-take and high lactate production, a malfunctioning calcium regulation or an increase in cell death.
- hGH Human growth hormone
- hGH-activity refers to any form of native, recombinant or synthetic polypeptide or protein exhibiting hGH-activity including all variants of hGH with functionally analogue activity, such as truncated forms, fragments thereof, forms with amended or extended amino acid sequence or derivatives of hGH including conjugates with complementary agents for modulating its characteristics.
- the definition shall also include other compounds with growth hormone activity or capacity of inducing growth hormone activity, such as: a) molecules mimicking hGH action having affinity to the hGH receptor and/or capability of activating the hGH receptor; or b) molecules having the capacity to release hGH from mammal tissues.
- the agents comprising hGH according to the present invention preferably can be conventional therapeutic formulations of hGH prepared for storage by including one or several optional additives of physiological characteristics (carriers, excipients or stabilizers) to provide lyophilized products or aqueous solutions which are aimed for parenteral administration, either directly, or after reconstitution with a physiological fluid.
- physiological characteristics carriers, excipients or stabilizers
- One such suitable hGH product is Genotropin® (as supplied by Pharmacia & Upjohn AB).
- Genotropin® as supplied by Pharmacia & Upjohn AB
- a number of other formulations of hGH which might be conceivable to use with present invention are discussed in the mentioned publication WO 95/28173.
- other administration forms would be conceivable for the skilled person to employ with the present invention, if they could be considered to provide an effective dose.
- the effective amount of hGH necessary to administer to treat the above mentioned complications will vary dependent on the patient and the administration form.
- the clinically skilled person will be able adjust doses and select the appropriate administration route in order to reach the desired, mentioned therapeutic effects and thereby survey the patients response with conventional methods and tests.
- Fig. 1 shows that the cell viability increases in cardiac myocytes after human growth hormone supplementation.
- Fig. 2 demonstrates that the transport of glucose increases in cardiac myocytes when stimulated with human growth hormone.
- Fig. 3 shows the influence of wortmannin on the glucose transport in cardiac myocytes stimulated by growth hormone.
- Fig. 4 shows apoptosis induced with mitomycin and SNAP and the effects obtained with GH and IGF-1 in the presence of and without wortmannin.
- Fig. 5 shows how glucose oxidation and palmitate oxidation are affected when cardiac myocytes are stimulated by growth hormone.
- Fig. 6 shows how Protein Kinase B (PKB) is activated in cardiac myocytes by growth hormone.
- This example aims to investigate whether that cardiac myocytes expresses functionally coupled Growth Hormone receptors and the metabolic effect of the hormone in these cells.
- Cardiac myocytes used in the current experiment were highly differentiated and prepared from mammals. Dulbeccos Modified Eagle's medium (DMEM), Penicillin and Streptomycin
- Cardiac myocytes were isolated according to conventional routines for preparation of primary cultures and maintained in Dulbeccos Modified Eagle's medium supplemented with penicillin (100 U/ml), streptomycin (100 ⁇ g/ml) and 10 % foetal bovine serum (FCS).
- Dulbeccos Modified Eagle's medium supplemented with penicillin (100 U/ml), streptomycin (100 ⁇ g/ml) and 10 % foetal bovine serum (FCS).
- Growth Hormone receptors were detected by Western Blotting method using solubilized membrane preparations or by using Flow Cytometric Analysis (Kamentsky L.A.(1973) Cytology automation, Adv. Biol. Med. Phys. 14:93). Cell viability was measured by using an assay kit, Ez4u by Biomedica. The method is based on the finding that intact cells are capable to reduce uncolored tetrazolium salts to colored derivatives, which are easily measured spectrophotometrically. This method discriminates between living and dead cells because the reduction process requires functional mitochondria which are inactivated after cell death. Thus, the amount of viable cells are directly proportional to OD.
- Glucose transport was measured as described by Hundal et al (1994). Briefly, cells were incubated in serum free medium for 4 hours followed by incubation with Growth Hormone for 60 minutes, if not otherwise stated. Then cell monolayers were rinsed with Krebs Ringer Bicarbonate buffer (KRB) pH 7.4. Glucose transport was quantified by incubating the cells in the presence of -1H-2-deoxy-glucose in KRB for 8 minutes. Non-specific uptake was determined by quantifying cell associated radioactivity in the presence of 10 ⁇ M cytochalasin B. Uptake of 2-deoxy-glucose was terminated by rapidly aspirating the radioactive medium, followed by three successive washes of cell monolayers with cold PBS. The cells were lysed in 0.5 M NaOH before liquid scintillation counting. Rates of glucose transport were normalized for protein content in each well.
- the membrane proteins were separated by SDS-polyacrylamide gel electrophoresis (8 % acrylamide) according to the method of Laemmli (1970).
- Cardiac myocytes were harvested according to standard techniques for adherent cells. The samples were separated on SDS-PAGE and transferred onto nitrocellulose membrane. The membrane was incubated in the presence of anti-GH receptor. Antibodies and antigen-antibody complexes were detected by a chemiluminescent method (ECL). The cells were immunostained with a-GHR antibodies and a secondary FITC-conjugated rabbit anti mouse F(ab)2. The analysis was performed with an EPICS XL flow cytometer using an 488 nm argon laser and 525 nm band pass filter. The results show that growth hormone receptors are available on the surfaces on the AT-1 cells. Functional coupling of the receptors were confirmed by activation STAT5, using a gel-shift assay revealing binding of the transcription factor to a specific nucleotide sequence, and the biological response demonstrated below.
- ECL chemiluminescent method
- the cardiac myocytes were incubated in serum free medium for 4 hours followed by 60 minutes incubation of GH of different doses in serum starved cells. As demonstrated in Fig. 2, an increase in glucose transport rate was seen. The doses, 200 and 2000 ng/ml, significantly increased the rate by 68 and 78 %, respectively.
- the cardiac myocytes were incubated in serum free medium with or without 1 ⁇ m wortmannin for 4 hours. During the last hour, the cells were either stimulated with 200 ng/ml of GH or as a reference with 100 ng/ml of IGF- 1.
- Glucose transport measurements were performed and as shown in Fig.3, the wortmannin treated cells does not respond with an increased transportation of glucose. This is due to that wortmannin effectively inhibits the signal transduction generated from the insulin receptor by its specific inactivation the signal transducer phosphoinositide 3-kinase (PI 3-kinase).
- Cardiac myocytes were grown and treated in accordance with Example 1.
- wortmannin abolishes the protection against apoptosis exerted by GH and IGF-I.
- the ability of wortmannin to abolish the protective capacity of GH provides further evidence that the beneficial effects of said hormone is mediated by an insulin-like signaling which involves PI3K.
- the cardiac myocytes were incubated in serum free medium for 4 hours and subsequently 3 ml medium was supplemented with l ⁇ C-glucose (0.2 ⁇ Ci/ml, 5mM glucose) +/- insulin/GH was added.
- Devices containing filter paper were mounted in the cultivation flasks, the screw caps were tightened and cells were incubated for additional hour at 37° C.
- Prior termination of the CO2 measurements 0.4 ml of hyamine solution was applied on filter paper followed by 0.4 ml of 4 M sulphuric acid injection into the medium. The flasks were then incubated for additional 60 minutes at room temperature on shaker.
- the cardiac myocytes were incubated in serum free medium for 4 hours and subsequently 3 ml medium supplemented with 14c-palmitate(120uM (0.2 ⁇ Ci)/ml) +/- insulin / GH was added to each flask.
- Devices containing filter paper were mounted in the cultivation flasks, the screw caps were tightened and cells were incubated for 1 hour at 37° C.
- Prior termination of the CO2 measurements 0.4 ml of hyamine solution was applied on filter paper followed by injection of 0.4 ml of 4 M sulphuric acid into the medium. The flasks were than incubated for additional 60 min. at room temperature on shaker.
- PKB protein kinase B
- cardiomyocytes express functionally coupled GH receptors.
- the examples further show that GH exerts both a metabolic and protective effect on the cardiac myocyte, as reflected by a stimulated glucose transport rate and an decreased rate of stress-induced cell death, respectively.
- the marked increase in cardiac myocyte glucose and fatty acid oxidation in response to GH treatment expands the scope of the present invention to a treatment which enhances the efficiency by which nutrients like glucose and fatty acids are converted to energy. This increased energy supply is anticipated to improve contractile function and efficiency of the heart.
- GH activates signal transducers, for example phosphoinositide 3 -kinase and activators downstream of this, which are important mediators of the insulin action for sustaining an adequate metabolism and protection against stress-induced cell death.
- signal transducers for example phosphoinositide 3 -kinase and activators downstream of this, which are important mediators of the insulin action for sustaining an adequate metabolism and protection against stress-induced cell death.
- the insulin-like effect exerted by GH is insulin independent and can hence be therapeutically used in situations where the insulin action is inhibited as is the case in insulin resistance appearing in diabetes or certain cases of acute and chronic heart failure.
- the therapeutic potential of GH treatment of the heart according to the present invention should not be limited to glucose transport and protection against cell death, as these effects are only proof of the principle that GH can act via the insulin signaling pathway.
- the GH action on the heart can be extended to further effects of insulin on muscle tissue, for example oxidative capacity, cellular differentiation state and contractile function.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE69803298T DE69803298T2 (en) | 1997-07-04 | 1998-06-26 | USE OF GROWTH HORMONE IN AGENTS FOR TREATING INSULIN RESISTANCE IN THE HEART |
EP98932685A EP1007085B1 (en) | 1997-07-04 | 1998-06-26 | Use of growth hormone in compositions for treating insulin resistance in the heart |
SI9830100T SI1007085T1 (en) | 1997-07-04 | 1998-06-26 | Use of growth hormone in compositions for treating insulin resistance in the heart |
DK98932685T DK1007085T3 (en) | 1997-07-04 | 1998-06-26 | Use of growth hormone in preparations for the treatment of insulin resistance in the heart |
JP50702099A JP2002511876A (en) | 1997-07-04 | 1998-06-26 | Use of growth hormone in a composition for treating insulin resistance in the heart and enhancing protein kinase B (PKB) activity |
NZ501961A NZ501961A (en) | 1997-07-04 | 1998-06-26 | A therapy for improving cellular function in a heart challenged by insulin resistance, thereby protecting the heart from complications arising from this condition |
AT98932685T ATE209042T1 (en) | 1997-07-04 | 1998-06-26 | USE OF GROWTH HORMONE IN AGENTS FOR TREATING INSULIN RESISTANCE IN THE HEART |
CA002294824A CA2294824A1 (en) | 1997-07-04 | 1998-06-26 | Use of growth hormone in compositions for treating insulin resistance in the heart and for enhancing protein kinase b (pkb) activity |
AU82506/98A AU737065B2 (en) | 1997-07-04 | 1998-06-26 | Use of growth hormone in compositions for treating insulin resistance in the heart and for enhancing protein kinase B (PKB) activity |
NO20000007A NO20000007L (en) | 1997-07-04 | 2000-01-03 | Use of growth hormone in compositions to treat insulin resistance in the heart and to increase protein kinase B (PKB) activity |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9702595-1 | 1997-07-04 | ||
SE9702595A SE9702595D0 (en) | 1997-07-04 | 1997-07-04 | new therapeutic use |
SE9802023-3 | 1998-06-08 | ||
SE9802023A SE9802023D0 (en) | 1998-06-08 | 1998-06-08 | New therapeutic use |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999001151A1 true WO1999001151A1 (en) | 1999-01-14 |
Family
ID=26663028
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/SE1998/001261 WO1999001151A1 (en) | 1997-07-04 | 1998-06-26 | Use of growth hormone in compositions for treating insulin resistance in the heart and for enhancing protein kinase b (pkb) activity |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP1007085B1 (en) |
JP (1) | JP2002511876A (en) |
AT (1) | ATE209042T1 (en) |
AU (1) | AU737065B2 (en) |
CA (1) | CA2294824A1 (en) |
DE (1) | DE69803298T2 (en) |
DK (1) | DK1007085T3 (en) |
ES (1) | ES2168772T3 (en) |
NO (1) | NO20000007L (en) |
NZ (1) | NZ501961A (en) |
PT (1) | PT1007085E (en) |
WO (1) | WO1999001151A1 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999064062A1 (en) * | 1998-06-08 | 1999-12-16 | Pharmacia & Upjohn Ab | New therapeutic use of pkb (proteine kinase b) enhancers |
WO2000067770A1 (en) * | 1999-05-05 | 2000-11-16 | Sahltech I Göteborg AB | Treatment of acute myocardial infarction with a substance related to the growth hormone axis |
WO2001068127A1 (en) * | 2000-03-13 | 2001-09-20 | Pharmacia Ab | Use of growth hormone in low dose |
AU2006200127B2 (en) * | 2000-03-13 | 2007-10-25 | Pfizer Inc. | Use of growth hormone in low dose |
RU2493868C2 (en) * | 2006-08-31 | 2013-09-27 | Новартис Аг | Pharmaceutical compositions containing hgh for oral administration |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995028173A1 (en) * | 1994-04-15 | 1995-10-26 | Genentech, Inc. | Treatment of congestive heart failure |
WO1997009060A1 (en) * | 1995-09-08 | 1997-03-13 | Eli Lilly And Company | Method of treating insulin resistance |
WO1997038709A1 (en) * | 1996-04-12 | 1997-10-23 | Pharmacia & Upjohn Ab | Use of growth hormone |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995028713A1 (en) * | 1994-04-18 | 1995-10-26 | Gay Freres Vente Et Exportation S.A. | Electronic memory device |
-
1998
- 1998-06-26 DK DK98932685T patent/DK1007085T3/en active
- 1998-06-26 EP EP98932685A patent/EP1007085B1/en not_active Expired - Lifetime
- 1998-06-26 NZ NZ501961A patent/NZ501961A/en unknown
- 1998-06-26 WO PCT/SE1998/001261 patent/WO1999001151A1/en active IP Right Grant
- 1998-06-26 CA CA002294824A patent/CA2294824A1/en not_active Abandoned
- 1998-06-26 ES ES98932685T patent/ES2168772T3/en not_active Expired - Lifetime
- 1998-06-26 AU AU82506/98A patent/AU737065B2/en not_active Ceased
- 1998-06-26 JP JP50702099A patent/JP2002511876A/en not_active Withdrawn
- 1998-06-26 DE DE69803298T patent/DE69803298T2/en not_active Expired - Fee Related
- 1998-06-26 AT AT98932685T patent/ATE209042T1/en not_active IP Right Cessation
- 1998-06-26 PT PT98932685T patent/PT1007085E/en unknown
-
2000
- 2000-01-03 NO NO20000007A patent/NO20000007L/en not_active Application Discontinuation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995028173A1 (en) * | 1994-04-15 | 1995-10-26 | Genentech, Inc. | Treatment of congestive heart failure |
WO1997009060A1 (en) * | 1995-09-08 | 1997-03-13 | Eli Lilly And Company | Method of treating insulin resistance |
WO1997038709A1 (en) * | 1996-04-12 | 1997-10-23 | Pharmacia & Upjohn Ab | Use of growth hormone |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999064062A1 (en) * | 1998-06-08 | 1999-12-16 | Pharmacia & Upjohn Ab | New therapeutic use of pkb (proteine kinase b) enhancers |
WO2000067770A1 (en) * | 1999-05-05 | 2000-11-16 | Sahltech I Göteborg AB | Treatment of acute myocardial infarction with a substance related to the growth hormone axis |
WO2001068127A1 (en) * | 2000-03-13 | 2001-09-20 | Pharmacia Ab | Use of growth hormone in low dose |
US6696414B2 (en) | 2000-03-13 | 2004-02-24 | Pharmacia Ab | Use of growth hormone in low dose |
US7229965B2 (en) | 2000-03-13 | 2007-06-12 | Pharmacia Ab | Use of growth hormone in low dose |
AU2006200127B2 (en) * | 2000-03-13 | 2007-10-25 | Pfizer Inc. | Use of growth hormone in low dose |
RU2493868C2 (en) * | 2006-08-31 | 2013-09-27 | Новартис Аг | Pharmaceutical compositions containing hgh for oral administration |
Also Published As
Publication number | Publication date |
---|---|
DE69803298T2 (en) | 2002-08-08 |
JP2002511876A (en) | 2002-04-16 |
DK1007085T3 (en) | 2002-05-13 |
EP1007085A1 (en) | 2000-06-14 |
PT1007085E (en) | 2002-05-31 |
NZ501961A (en) | 2001-11-30 |
NO20000007L (en) | 2000-03-06 |
AU737065B2 (en) | 2001-08-09 |
ATE209042T1 (en) | 2001-12-15 |
DE69803298D1 (en) | 2002-02-21 |
AU8250698A (en) | 1999-01-25 |
NO20000007D0 (en) | 2000-01-03 |
ES2168772T3 (en) | 2002-06-16 |
EP1007085B1 (en) | 2001-11-21 |
CA2294824A1 (en) | 1999-01-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Straus | Growth-stimulatory actions of insulin in vitro and in vivo | |
Ginsberg | The insulin receptor: properties and regulation | |
Mössner et al. | Insulin, via its own receptor, regulates growth and amylase synthesis in pancreatic acinar AR42J cells | |
Marsden et al. | Tumor necrosis factor alpha activates soluble guanylate cyclase in bovine glomerular mesangial cells via an L-arginine-dependent mechanism. | |
Patti et al. | Bidirectional modulation of insulin action by amino acids. | |
Abraham et al. | Vanillin, a potential agent for the treatment of sickle cell anemia | |
Cheung et al. | Tumor necrosis factor-alpha induces hepatic insulin resistance in obese Zucker (fa/fa) rats via interaction of leukocyte antigen-related tyrosine phosphatase with focal adhesion kinase. | |
US4900747A (en) | Method and agents for removing advanced glycosylation endproducts | |
Chow et al. | Growth hormone stimulates tyrosine phosphorylation of JAK2 and STAT5, but not insulin receptor substrate-1 or SHC proteins in liver and skeletal muscle of normal rats in vivo | |
Nakano et al. | Tumor necrosis factor-alpha-induced expression of heat shock protein 72 in adult feline cardiac myocytes | |
Kahn et al. | Nitric oxide: the “second messenger” of insulin | |
Zheng et al. | Lysozyme enhances renal excretion of advanced glycation endproducts in vivo and suppresses adverse age-mediated cellular effects in vitro: a potential AGE sequestration therapy for diabetic nephropathy? | |
Ritchie | Interleukin 6 stimulates hepatic glucose release from prelabeled glycogen pools | |
JP2001516726A (en) | Prevent miscarriage | |
Yang et al. | Effects of insulin on cultured rat brain cells: stimulation of ornithine decarboxylase activity | |
Freeman et al. | Inhibition of system A amino acid transport and hepatocyte proliferation following partial hepatectomy in the rat | |
Wang et al. | Coordinate regulation of glucose transporter function, number, and gene expression by insulin and sulfonylureas in L6 rat skeletal muscle cells. | |
EP1007085B1 (en) | Use of growth hormone in compositions for treating insulin resistance in the heart | |
Matthews et al. | 12-O-tetradecanoylphorbol-13-acetate stimulates phosphorylation of the 58,000-Mr form of polyomavirus middle T antigen in vivo: implications for a possible role of protein kinase C in middle T function | |
JP6716187B2 (en) | Adiponectin receptor agonist peptide | |
Pezzino et al. | Regenerating rat liver: insulin and glucagon serum levels and receptor binding | |
Rochet et al. | Effect of a thermogenic agent, BRL 26830A, on insulin receptors in obese mice | |
US6727285B1 (en) | Use of D-arginine and/or L-arginine to protect the amino groups of biological substances from damage, inactivation, or modification by toxic carbonyls and/or dicarbonyls | |
Venkatesan et al. | Insulin resistance in rats harboring growth hormone—secreting tumors: Decreased receptor number but increased kinase activity in liver | |
Boyle et al. | Effect of rhIGF-I infusion on whole fetal and fetal skeletal muscle protein metabolism in sheep |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 82506/98 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 501961 Country of ref document: NZ |
|
ENP | Entry into the national phase |
Ref document number: 2294824 Country of ref document: CA Ref country code: CA Ref document number: 2294824 Kind code of ref document: A Format of ref document f/p: F |
|
NENP | Non-entry into the national phase |
Ref country code: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998932685 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1998932685 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1998932685 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 82506/98 Country of ref document: AU |